News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SCOLR Pharma, Inc. (DDD) Launches Cutting Edge Nutritional Products at Major Retailers in 2012


2/17/2012 9:41:43 AM

BOTHELL, Wash., Feb. 16, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) announced today that it has launched several new extended-release nutritional/vitamin products based on the Company's patented oral drug delivery platform, Controlled DeliveryTechnology (CDT®). Eleven class-leading products are now being sold under various private label brands across the country at the nation's top retail chains.

Each product has been designed to deliver the full nutritional or vitamin dosage over a period of time from 12 to 24 hours. The products are available on the vitamin/nutritional supplement aisles and are easily identifiable by their 12 or 24 Hour package logo and/or Extended Release or Controlled Release nomenclature.

The Company's flagship extended release formulations are Niacin 500mg 12HR Controlled-Release, Vitamin C 1000 mg 12HR, CoQ-10 100 mg 24HR, Glucosamine Chondroitin MSM Advanced 12HR Combo, and three 24HR calcium formulations; Calcium 1200 +D with calcium citrate, Calcium + Vitamin D Plus Minerals, and Calcium + Vitamins D & K.

The Company has plans later this year to launch several new nutritional/vitamin products under its house brand SCOLR® and for additional private label products with new and existing retailers.

Stephen J. Turner, SCOLR Pharma's President and CEO, said, "This is an exciting and landmark step for SCOLR. The acceptance by so many retailers of our nutritional products indicates there is a strong consumer demand for extended release nutritional products and vitamins. We are very enthused about the business opportunity this represents for SCOLR and our patented technologies. "

About SCOLR Pharma:
Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

Forward looking statements:
Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements regarding anticipated developments in the Company's nutritional business. Factors that could cause these forward-looking statements to differ from actual results include delays in manufacturing, labeling or shipment of products, order revisions, or variations in retailer's marketing plans, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Contacts:
Investor Relations:
SCOLR Pharma, Inc.
425.368.1050

SOURCE SCOLR Pharma, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES